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Inappropriate medication use is a major patient safety concern, especially for the elderly
population. Amitriptyline is widely used in primary care in South Africa and a cross-sectional
study found that amitriptyline was prescribed potentially inappropriately in 6.5% of elderly
patients. An analysis of prescriptions from the Chronic Dispensing Unit in the Western Cape
revealed that amitriptyline was one of the most common medicines prescribed without a
suitable diagnosis listed on the prescription.
Objective
The main objective of the medicine use evaluation (MUE) was to determine whether amitrip-
tyline was prescribed in accordance with recommendations from standard treatment guide-
lines (STG) and essential medicines lists (EML) endorsed by the National Department of
Health, South Africa.
Methods
A retrospective, cross-sectional, multicentre review of patients’ clinical notes was con-
ducted. The study population was selected by systematic random sampling from adult out-
patients who were prescribed amitriptyline for longer than three months. Criteria for
evaluation included amitriptyline indication and total daily dose prescribed.
Results
Of the sample of 2237 patient medical records reviewed, 1732 (77.4%) included amitripty-
line prescriptions that were according to the approved STG indications. For the approved
STG indications, amitriptyline was prescribed mainly for osteoarthritis (25.8%), neuropa-
thies (18.5%) and chronic non-cancer pain (17.9%). Major depressive disorders constituted
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only 8.6% of the patient records reviewed; however, doses were atypically low. The main
inappropriate indication for amitriptyline was sleep disorders (16%).
Conclusion
This MUE has highlighted the need to improve the use of amitriptyline in specific patient pop-
ulations, e.g. the elderly and patients with sleeping disorders.
Background
Access to essential medicines is critical in addressing health problems and improving the qual-
ity of lives of millions of patients around the world. Medicines form an indispensable compo-
nent of any healthcare system in the prevention, diagnosis and treatment of diseases and in
alleviating disability and functional deficiency. Essential medicines are defined as “medicines
that satisfy the priority healthcare needs of the population,” with the concept being that these
medicines are intended to be available at all times, in adequate amounts, in appropriate dosage
forms, with assured quality and at a price that the individual and country can afford.[1] The
World Health Organization (WHO) further states that rational use of medicines require that
“patients receive medication appropriate to their clinical needs, in doses that meet their own
individual requirements, for an adequate period of time, and at the lowest cost to them and
their community”.[2]
Taking the above two concepts into consideration, the prescribing of medicines should gen-
erally follow these steps: (a) Determine the diagnosis of the patient; (b) Consider effective and
safe treatment options; (c) Select appropriate medicines, which include dose, frequency and
duration; (d) Write a clear prescription; (e) Provide patients with the necessary information or
counselling; and (f) Follow up to evaluate treatment responses.[3] However, prescribing pat-
terns do not always conform to these ideals, resulting instead in inappropriate and irrational
prescribing.[4]
The impact of irrational medicine use can have varying effects on patients and the risk of
adverse drug reactions (ADRs) is increased. In older patients the presence of a comorbidity is
a strong predictor of repeat admissions for ADRs, especially if they are managed and treated in
the community setting.[5] Irrational prescribing can also expose patients to the possibility of
developing drug dependence to certain medicines, such as analgesics and tranquillizers.[6]
Not only does inappropriate use of medicines have a negative effect on patients, but it also
leads to wastage of scarce resources. The WHO estimated that the appropriate use of medicines
can result in about 50%–70% cost-efficiency in medicines expenditure.[7]
Inappropriate medication use is a major patient safety concern, especially for the elderly
population.[8] In 1987 and 1992, it was reported that between 17.5% and 23.5% of commu-
nity-dwelling elderly patients in the United States used at least 1 of 20 potential inappropriate
medicines.[9] The most frequently prescribed potentially inappropriate medications were
diazepam, propoxyphene, dipyridamole, amitriptyline, and chlordiazepoxide; these medicines
accounted for 85% of the outpatient visits involving potentially inappropriate medications.[10]
A cross-sectional study, including 103 420 patients aged�65 years, that was conducted using a
database obtained from a pharmaceutical benefit management company in South Africa
found that amitriptyline was prescribed potentially inappropriately in 6.5% (n = 36 509) of
elderly patients.[11]
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Amitriptyline is widely used in primary care in South Africa as it is listed as an Essential
medicine in South Africa. In the Western Cape, data from the provincial medicine warehouse,
the Cape Medical Depot (CMD), indicated an annual consumption of more than 600 000
packs (included 28s, 56s, 84s and 168s) of amitriptyline 10mg or 25mg with an expenditure of
R3.5million (US$231 500.00) for the period July 2016 to June 2017.[12] An analysis done on
prescriptions at the Chronic Dispensing Unit in the Western Cape revealed that amitriptyline
was one of the most common medicines prescribed without a diagnosis listed on the prescrip-
tion.[13] Thus, concerns for inappropriate prescribing, together with the wide use and poten-
tial for adverse effects, led to the Provincial Pharmacy and Therapeutics Committee (PTC) of
the Western Cape requesting that a review of the use of amitriptyline be conducted. To our
knowledge limited to no data exists on medicine use evaluations for mental health medicines
in low to middle income countries (LMICs). Our objective was to establish if amitriptyline is
prescribed according to the recommendations set out in the Standard Treatment Guidelines
[14, 15] developed by the South African Department of Health.
Method
A retrospective, multicentre review of clinical notes of outpatients was conducted in the public
health care sector of the Western Cape. The study population included adult outpatients (�18
years of age) who received amitriptyline for longer than 3 months during the period 01 April
2016 to 31 July 2017.
The folder review was performed between 27 March 2017 and 31 July 2017. A convenience
sample of facilities was selected from health facilities that had at least one fulltime pharmacist
and doctor. According to South African legislation, amitriptyline (as a schedule 5 medicine)
should be prescribed by a doctor. Facilities with low amitriptyline numbers were excluded. At
least 30 folders per facility were selected by random systematic selection and reviewed over a 2
to 4-week period within the study period. The sample size was based on the World Health
Organization recommendation of 30 folders per facility [16]. The data was sourced from
patients’ clinical records using a data collection tool developed by a multi-disciplinary team
that included pharmacists and doctors working in the healthcare facilities. A pilot study was
done at one facility to determine ease of use of the data collection tool as well as to determine if
the required analysis could be done with the variables collected. Data collected included demo-
graphic data (gender and age), diagnosis, medication prescribed, comorbidities and amitripty-
line dosages. Information collected was captured onto a predesigned Microsoft1Office Excel
(Microsoft, USA) spreadsheet, from where analyses were performed. Descriptive statistics
were used to report proportions and percentages of the outcomes. P-values�0.05 were consid-
ered significant.
The criteria used for evaluation were diagnosis-related. The criteria were determined by
using the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) for Pri-
mary Health Care (2014)[14] and Adult Hospital Level (2015)[15]. These guidelines were in
use at the time of the review. Table 1 lists the STGs and EML indications for amitriptyline use.
Table 1. Indications for amitriptyline according to Standard Treatment Guidelines[14, 15].
1. Major depressive disorders (MDD) (F32.9)
2. Pain associated with:
Neuropathies (E10.2/E11.2/N08.3) Rheumatoid arthritis (M05.9/M06.9) Herpes zoster (B20.3)
Cancer, non-cancer / other (R52.9) Osteoarthritis (M19.9) Migraine (G43)
https://doi.org/10.1371/journal.pone.0231675.t001
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To facilitate data collection, the following non-EML indications were added to the data col-
lection tool: irritable bowel syndrome, anxiety, sleeping disorders and overactive bladder.
Diagnoses had to be documented unambiguously (not symptoms) in the medical notes to be
accepted. Diagnoses that were not listed on the tool or unclear were included as ‘other non-
pain indications’. Folders were reviewed independently and discrepancies were resolved
amongst the authors.
A threshold refers to the percentage of charts or records that will meet or exceed the estab-
lished criteria for the medicine. Ideally, this threshold will be 100 percent, but realistically, a
smaller percentage will be more appropriate to account for exceptions to routine medicine pre-
scribing. The threshold was set at 99% as amitriptyline is prescribed predominantly at primary
healthcare level. It is expected that 99% of prescriptions should comply with the STG & EML
with regards to the diagnosis, dosage and process issues. A deviation of 1% was allowed for
exceptions. The threshold was jointly decided upon by a multidisciplinary team.
Ethical considerations
Approval to conduct the study was granted by the Western Cape Pharmacy and Therapeutics
Committee, the Western Cape Government Health (WC_201806_021) as well as the Univer-
sity of the Western Cape’s Biomedical Research Ethics Committee (BM18/4/5). For the pur-
pose of the folder review informed consent from patients were not required by the approval
committees as this study was retrospective, data was anonymized before analysis and there was
no direct patient contact.
Results
Out of 193 health facilities where amitriptyline was prescribed, 102 facilities were excluded due
to low amitriptyline numbers (i.e. < 15 prescriptions per week). Thus, out of the 91 facilities,
sixty-four facilities (70.3% response rate) contributed to the review of amitriptyline use in the
Western Cape. A total of 2237 patient folders were reviewed. These patients received amitrip-
tyline for a period of longer than three months. Metropole facilities, rural facilities and trans-
verse facilities (e.g. tertiary hospitals that serve patients across the province) made up 75%,
17% and 8%, respectively, of the sample. Graph 1 indicates the contribution to the sample by
the type of facility. Community Day Centres (CDCs), Community Health Centres (CHCs) and
clinics contributed 80% towards the total sample, while hospital outpatients made up 20% of
the sample (Fig 1).
Demographic information is shown in Table 2. There were two and a half times more
females (1639; 73%) than males (597; 27%) receiving amitriptyline. The average age of the
patients was 57 years (SD±13.81). Females were on average 2 years older than males, with the
average age being 58 years and 56 years, respectively (p<0021).
For the prescriptions reviewed, 1732 (n = 2237; 77.43%) prescriptions for amitriptyline
were according to indications approved in the STGs. Thus, almost a quarter of patients
received amitriptyline for indications not listed or approved in the STGs.
As more than one indication was reported for some folder reviews of patients with co-mor-
bidities, a total of 2688 indications for use of amitriptyline were reported in the total sample
(n = 2237). The proportion of prescriptions by indication is shown in graph 2 (Fig 2). For the
approved STG indications (Table 1), amitriptyline was prescribed mainly for osteoarthritis
(25.79%), followed by chronic non-cancer pain (17.88%). Major depressive disorders consti-
tuted 8.58%, while all neuropathies combined constituted 18.45% of the patient medical rec-
ords reviewed. At 16.00%, sleeping disorders made up the highest proportion of patient folder
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reviews for a Non-STG indication and this also constituted the indication with the third high-
est proportion of all folders reviewed.
Table 3 provides information on sex, age and dose per indication. The most common indi-
cation within the female sub-group was osteoarthritis/osteoarthrosis (27.9%) and for males it
was neuropathies (25.6%). Elderly patients are prone to side effects of amitriptyline. Amitripty-
line increases the risk of urinary retention in males over 55 years old, thus the age sub-groups
were split into patients that are�55 years and patients above 55 years old. The proportion of
patients over 55 years were 54%, 55% and 50% for the total sample, females and males, respec-
tively. Doses were split into�50mg and>50mg. Around 95% of the doses prescribed for ami-
triptyline were� 50mg daily; with 86% of these doses being� 25mg daily. For the STG
indications (n = 1732), at least 95% of doses were within guideline recommendations. Doses
for the Non-STG indications could not be assessed as there were no clinical practice guidelines
in place to use as a reference for these indications.
Further analysis showed that for males over 55 years, only 9% of patients in this risk group
were on doses greater than 25mg daily. For patients that were� 65 years, doses were generally
in the lower range, i.e. 87% of the doses were� 25mg daily and another 10% of doses
were> 25mg but� 50mg.
Only 1% of the doses were� 125mg daily and these doses were prescribed for indications
such as major depressive disorder (MDD), anxiety disorder (Non-STG indication), sleep
Fig 1. Proportion of folders reviewed by facility type.
https://doi.org/10.1371/journal.pone.0231675.g001
Table 2. Gender descriptive statistics (n = 2237).
n Mean age Standard deviation Min age Max age Median Age: CI 95%
Female 1639 (73%) 58 13.31 18 99 57 57.01–58.30
Male 597 (27%) 56 14.99 18 93 56 54.44–56.85
Total 2237� (100%) 57 13.81 18 99 57 56.54–57.69
�One patient with missing gender
https://doi.org/10.1371/journal.pone.0231675.t002
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disorder (Non-STG indication) and osteoarthritis. Although infrequent, high doses (�125mg
daily) of amitriptyline for osteoarthritis were of concern as this was not in line with STG
recommendations.
For MDD, 70% of the prescriptions had a dose of� 25mg daily and a further 20% had a
dose of 50mg daily. Of these prescriptions, only 41% had another antidepressant or mood sta-
biliser added, implying that these patients on amitriptyline monotherapy may be sub-optimally
managed.
Table 4 indicates amitriptyline prescribed with other pain modulating medicines. Paraceta-
mol was widely used in combination with amitriptyline, with just under two thirds of the pre-
scriptions having this combination. Furthermore, a third of the prescriptions comprised
amitriptyline with tramadol. Amitriptyline on its own was predominantly prescribed for sleep
Fig 2. Proportion of prescriptions by indication of use.
https://doi.org/10.1371/journal.pone.0231675.g002
Table 4. Concomitant pain medicine use.
Pain Medicines Quantity Percentage
Amitriptyline
Amitriptyline only 690 30.84%
+ Paracetamol
Paracetamol all 1398 62.49%
Paracetamol only 478 21.37%
+Ibuprofen/NSAID
Ibuprofen/NSAID all 466 20.83%
NSAID only 72 3.22%
+Tramadol
Tramadol all 748 33.44%
Tramadol only 60 2.68%
https://doi.org/10.1371/journal.pone.0231675.t004
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disorders and neuropathies. Amitriptyline with paracetamol only (as only other pain-modulat-
ing medicine) was predominantly prescribed for neuropathies, osteoarthritis and other
chronic non-cancer pain. For amitriptyline with non-steroidal anti-inflammatory drugs
(NSAIDs) only or tramadol only, osteoarthritis and other chronic non-cancer pain were the
main indications.
Table 5 compares the thresholds set and results observed for the STG indications, appropri-
ate dosing and clear documentation. Observed results of 77%, 95% and 90% were achieved,
respectively. The proportion calculated for ‘appropriate dosing’ was estimated from prescrip-
tions with STG indications only as no recommendation on dosing is provided for Non-STG
indications.
Discussion
With an unknown proportion of the population that would be adherent to guidelines, a propor-
tion of 50% (i.e. ρ = 0.5) and a confidence interval of 95% were used to calculate the sample size
required i.e. 384. In order to expose all facilities that matched our inclusion criteria to the MUE
methodology and requiring at least 30 patient medical record reviews per facility, a total of 2237
patient medical records were reviewed; this was well within the calculated sample size. In the
Western Cape, the approach for patient care is that, generally, around 85% of patients should
receive healthcare at a primary level, around 12% at hospital level and around 3% at a tertiary care
level. Furthermore, the indications for amitriptyline, including follow-up after referral from hospi-
tal level, falls mainly within the ambit of primary care. Thus, as 80% of the sample was made up
from primary care level patients, this indicated a fair representation of the patient distribution.
In South Africa, the Standard Treatment Guidelines and Essential Medicines List (STGs)
are evidence-based medicine recommendations aimed to cater for most of the population
[14,15]. Adherence to these recommendations is expected from all public sector healthcare
facilities to ensure an effective standard of care, safety and equitable access to medicines. As
amitriptyline was used predominantly at primary care according to consumption data, adher-
ence to the STGs was expected to be high; and thus, a high threshold (99%) was set for what is
considered appropriate prescribing of amitriptyline in the province.
In our review the majority of the ambulatory patients received amitriptyline as per STGs,
mainly as an adjunct for pain control in chronic pain conditions. However, almost one quarter
of the prescriptions were for indications that are not in line with the STGs and thus, there is
room for improvement. Around 16% of the patients were on amitriptyline for sleep disorders
and this may suggest a need for appropriate sleep disorder management opportunities within
the public sector. According to the STGs, sleep hygiene and stimulus control are the first steps
of treatment; and if medication is required, short-term benzodiazepines are the preferred
agents to use for the treatment of insomnia. Non-benzodiazepines tend not to be abused in
comparison to benzodiazepines, are effective in insomnia and may offer a better safety profile
over benzodiazepines. However, the use of amitriptyline for insomnia is regarded as off-label
use. Low-dose amitriptyline has been used successfully in patients with insomnia, but is con-
traindicated in suicidal patients or in those with cardiac risk factors. It is generally




Recording of diagnosis information 99% 90%
https://doi.org/10.1371/journal.pone.0231675.t005
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recommended that antidepressants be prescribed at therapeutic doses when insomnia coexists
with a mood disorder.[17] The STGs, therefore, recommend referral of patients that cannot be
managed utilising cognitive behaviour methods or short-term benzodiazepines.
The use of low dose amitriptyline in major depressive disorders raised concerns for possible
inappropriate management of these conditions. Low doses of amitriptyline for treating mood
disorders may not only be ineffective but could also produce unwarranted adverse effects in
patients. The lifetime prevalence for major depression in South Africa is 9.8%[18]. In a study
conducted in the private healthcare sector of South Africa, only 26.2% of patients who received
amitriptyline-containing products were compliant[19]. This raises further concerns when tak-
ing under dosing, as seen in our study, into consideration. Ineffective treatment of mood dis-
orders has a substantial risk for suicide.
A third of the patients were on tramadol and amitriptyline, concurrently, and this combina-
tion can induce constipation, precipitate urinary retention in elderly men, lower the seizure
threshold and cause serotonin syndrome. The current STGs do not provide any recommenda-
tion on education or precautions on the potential risk of serotonin syndrome. This review
highlights the potential risk of serotonin syndrome in this population.
The highest proportion of prescriptions was indicated for osteoarthritis (26%); however,
there is limited evidence for recommending amitriptyline therapy for inflammatory arthritis
and some evidence of benefit in fibromyalgia, but no evidence of benefit of amitriptyline in
osteoarthritis.[20] Also, in a systematic review to determine effectiveness of amitriptyline in
musculoskeletal pain and improved functionality, it was concluded that amitriptyline may be
effective, but further research is needed to establish efficaciousness and the specific indication
(s) for amitriptyline.[21] A Cochrane review is underway, currently, to determine the safety
and efficacy of antidepressants for osteoarthritis.[22] Thus, due to safety concerns and a pau-
city of evidence of efficacy of amitriptyline in osteoarthritis, amitriptyline was not included in
the South African Primary Health Care STG for this indication. Preferably, amitriptyline
should therefore not be initiated at primary care level for this indication, especially, because of
potential cardiotoxicity in patients with co-morbid cardiovascular conditions. Amitriptyline,
however, remains listed in the Adult Hospital STG for osteoarthritis as adjunctive therapy for
pain control as this is considered standard of care, currently, and there is uncertainty as to
whether amitriptyline is not efficacious[15].
The mean age of the sample was 57 (±14) years and older patients often have multiple dis-
eases, especially co-morbid cardiovascular conditions, requiring multiple medicines; this
increases the potential for using inappropriate medicines and ultimately results in various
adverse effects. In elderly patients there exist concerns with the use of anticholinergic drugs
due to potential confusion, constipation, urination problems, blurry vision and low blood
pressure. This review highlighted the importance of considering the benefit (effectiveness) ver-
sus the risks when prescribing amitriptyline, especially due to the patient groups involved.
Conclusion
This review has highlighted the importance of evaluating patients’ need for amitriptyline when
receiving it for chronic use. In these public healthcare facilities, there is a need to improve the use
of amitriptyline in specific patient populations, e.g. elderly men, patients with major depressive
disorders, patients with sleeping disorders or with co-morbid cardiovascular conditions.
Supporting information
S1 File. De-identified data set.
(XLSX)
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